CN112155625A - Medicine-carrying degradable blood vessel anastomat - Google Patents
Medicine-carrying degradable blood vessel anastomat Download PDFInfo
- Publication number
- CN112155625A CN112155625A CN202010901258.4A CN202010901258A CN112155625A CN 112155625 A CN112155625 A CN 112155625A CN 202010901258 A CN202010901258 A CN 202010901258A CN 112155625 A CN112155625 A CN 112155625A
- Authority
- CN
- China
- Prior art keywords
- drug
- vascular
- anastomat
- iron core
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004204 blood vessel Anatomy 0.000 title abstract description 16
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 42
- 229940079593 drug Drugs 0.000 claims abstract description 35
- 230000002792 vascular Effects 0.000 claims abstract description 32
- 230000003872 anastomosis Effects 0.000 claims abstract description 16
- 229910052742 iron Inorganic materials 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims description 21
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 14
- 239000004626 polylactic acid Substances 0.000 claims description 14
- 230000033115 angiogenesis Effects 0.000 claims description 10
- 230000001737 promoting effect Effects 0.000 claims description 10
- 102000008186 Collagen Human genes 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 9
- 229920001436 collagen Polymers 0.000 claims description 9
- 229910052802 copper Inorganic materials 0.000 claims description 9
- 239000010949 copper Substances 0.000 claims description 9
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 9
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 102100022987 Angiogenin Human genes 0.000 claims description 5
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 5
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 5
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- 108010072788 angiogenin Proteins 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- OFBLZCXWVROESG-UHFFFAOYSA-N 1,2,3-trihydroxyheptan-4-one Chemical compound CCCC(=O)C(O)C(O)CO OFBLZCXWVROESG-UHFFFAOYSA-N 0.000 claims description 4
- 102000013537 Thymidine Phosphorylase Human genes 0.000 claims description 4
- 108700023160 Thymidine phosphorylases Proteins 0.000 claims description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims 2
- 230000006444 vascular growth Effects 0.000 claims 2
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 1
- 125000003259 prostaglandin group Chemical group 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract description 12
- 238000006731 degradation reaction Methods 0.000 abstract description 12
- 230000004069 differentiation Effects 0.000 abstract description 8
- 231100000241 scar Toxicity 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 210000005167 vascular cell Anatomy 0.000 abstract description 7
- 208000032544 Cicatrix Diseases 0.000 abstract description 6
- 230000037387 scars Effects 0.000 abstract description 6
- 230000000451 tissue damage Effects 0.000 abstract description 6
- 231100000827 tissue damage Toxicity 0.000 abstract description 6
- 230000014759 maintenance of location Effects 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 abstract description 2
- 102000001554 Hemoglobins Human genes 0.000 abstract description 2
- 108010054147 Hemoglobins Proteins 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 229910001448 ferrous ion Inorganic materials 0.000 abstract description 2
- -1 iron ions Chemical class 0.000 abstract description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 10
- 239000005749 Copper compound Substances 0.000 description 9
- 150000001880 copper compounds Chemical class 0.000 description 9
- 230000001023 pro-angiogenic effect Effects 0.000 description 8
- 239000002131 composite material Substances 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/11—Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
- A61L31/088—Other specific inorganic materials not covered by A61L31/084 or A61L31/086
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00893—Material properties pharmaceutically effective
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/11—Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
- A61B2017/1107—Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis for blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a drug-loaded degradable vascular anastomat which is characterized by comprising main components which are symmetrically arranged, wherein each main component comprises a clamping part, a puncturing part and a matching hole, and the puncturing parts and the matching holes are symmetrically arranged on the clamping parts respectively; and the puncturing parts of the adjacent main parts are matched and connected with the matching holes. According to the invention, through controllable degradation, the risk caused by retention of the vascular anastomat is reduced, the strength of the puncture part can be ensured through the pointed iron core, the anastomosis effect is ensured, meanwhile, the iron core can be degraded, and the degraded component ferrous ions or iron ions are beneficial to formation of hemoglobin and blood transportation; and can promote the growth and differentiation of vascular cells through drug loading, accelerate the anastomosis of blood vessels at the anastomotic site, reduce the generation of scars and reduce the tissue damage to the maximum extent.
Description
Technical Field
The invention belongs to the technical field of medical instruments, and particularly relates to a drug-loading degradable vascular anastomat.
Background
In vascular surgery, suturing of blood vessels is a necessary operation, and generally involves manual suturing of stapler anastomoses. The manual suturing method is used for over 15 minutes, so that the surgical risk and cost of a patient are increased, a doctor is greatly burdened, meanwhile, the manual suturing is based on the skill, physical strength and proficiency of the doctor, the suturing quality is uneven, a certain risk is brought to postoperative recovery of the patient, and complications are seriously generated. The anastomat replaces the traditional manual suturing equipment, is reliable in quality, and has the advantages of convenience in use, particularly high suturing speed, simplicity and convenience in operation, few side effects and the like.
Present anastomat all is nondegradable anastomat usually, need use comparatively accurate and bulky anastomat or supporting apparatus, and remaining at internal anastomat nondegradable of postoperative can bring long-term foreign body sensation for the patient, and nondegradable anastomat stays internally for a long time simultaneously, can coincide at the blood vessel and go out to form the arch, and pit and scar etc. can influence blood flow speed, have brought long-term postoperative secondary damage risk and thrombus risk for the patient. Aiming at the problems, the invention provides a drug-loaded degradable vascular anastomat.
Disclosure of Invention
In view of the above, the invention provides a drug-loaded degradable vascular anastomat, which reduces risks caused by retention of the vascular anastomat through controllable degradation, can ensure the strength of a puncture part through a pointed iron core, ensures an anastomosis effect, is degradable, and is beneficial to formation of hemoglobin and blood transportation due to degradation components of ferrous ions or iron ions; and can promote the growth and differentiation of vascular cells through drug loading, accelerate the anastomosis of blood vessels at the anastomotic site, reduce the generation of scars and reduce the tissue damage to the maximum extent.
The technical scheme of the invention is as follows:
the drug-loaded degradable vascular anastomat is characterized by comprising main components which are symmetrically arranged, wherein each main component comprises a clamping part, a puncturing part and a matching hole, and the puncturing parts and the matching holes are symmetrically arranged on the clamping parts respectively;
and the puncturing parts of the adjacent main parts are matched and connected with the matching holes.
Furthermore, the puncture part is a pointed iron core, so that the strength of the puncture part is ensured; the medicine layer is coated on the outer part of the puncture part, and can promote the growth and differentiation of blood vessel cells.
Further, the clamping part is annular, and a channel for passing blood vessels is provided in the middle.
Furthermore, the clamping part comprises an easily degradable material body, so that rapid degradation can be ensured, and the clamping part is prevented from dissociating to other places; the outer layer of the body is coated with an iron-based coating which, when activated, slows the rate of degradation.
Furthermore, the matching hole is a hole tightly matched with the pointed iron core, so that clamping of the blood vessel can be ensured, and blood leakage is avoided.
Furthermore, the chamfered structure is arranged on the outer side of the pointed iron core, so that the blood vessel is prevented from slipping, and blood leakage is avoided.
Further, the pointed iron core is an iron core containing copper or a copper compound, and the copper or the copper compound can promote the growth and differentiation of vascular cells.
Further, the main part comprises at least 3 piercing parts.
Further, the drug layer is a mixture comprising a carrier and a pro-angiogenic factor or a pro-angiogenic factor.
Further, the carrier is one or a composite of a plurality of biodegradable materials such as polylactic acid, hydroxyapatite, collagen and the like.
Furthermore, the easily degradable body material of the clamping part is one or a composite of a plurality of biodegradable materials such as polylactic acid, hydroxyapatite, collagen and the like.
Furthermore, the angiogenesis promoting factor is one or more of prostaglandin, butyrylglycerol, hyaluronic acid metabolite, metal copper compound, vascular endothelial growth factor, and peptide angiogenesis factors such as aFGF, bFGF, angiogenin, PD-ECGF, TGF, TNF, etc.
According to the invention, through controllable degradation, the risk caused by retention of the vascular anastomat is reduced, the strength of the puncture part can be ensured through the pointed iron core, and the action effect is ensured; and can promote the growth and differentiation of vascular cells through drug loading, accelerate the anastomosis of blood vessels at the anastomotic site, reduce the generation of scars and reduce the tissue damage to the maximum extent.
The invention has the beneficial effects that:
1. degradation, which reduces the risks brought by the detention of the vascular anastomat, such as thrombus, vascular scar, limited pulsation of blood vessels, change of the biomechanics of blood vessels, and the like;
2. and (3) controllable degradation, wherein degradation sequence and rate are controlled by adopting different degradable materials at different positions. The complete degradation sequence comprises a medicine layer, a pointed iron core and a clamping part.
3. The pointed iron core used in the invention can ensure the strength of the puncture part and the effect;
4. the drug is loaded, so that the growth and differentiation of vascular cells are promoted through the drug loading, the anastomosis of blood vessels at the anastomosis position is accelerated, the generation of scars is reduced, and the tissue damage is reduced to the greatest extent.
Drawings
FIG. 1 is a schematic structural view of the present invention;
FIG. 2 is a schematic structural view of the main components of the present invention;
FIG. 3 is a schematic structural view of the main components of the present invention;
FIG. 4 is a schematic structural diagram of a main part according to an embodiment of the present invention;
fig. 5 is a schematic structural diagram of a main component according to an embodiment of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The drug-loaded degradable vascular anastomat is characterized by comprising main components 10 which are symmetrically arranged, wherein each main component comprises a clamping part 1, a puncture part 2 and a matching hole 3, and the puncture parts and the matching holes are symmetrically arranged on the clamping parts respectively;
and the puncturing parts of the adjacent main parts are matched and connected with the matching holes.
Further, the puncturing part is a pointed iron core, and a medicine layer 21 is coated outside the puncturing part.
Further, the clamping portion is annular.
Further, the clamping portion comprises a body 11 of a readily degradable material, the outer layer of which is coated with an iron-based coating 12.
Further, the matching hole is a hole which is in close fit with the pointed iron core.
Further, a chamfered structure 22 is arranged on the outer side of the pointed iron core.
Further, the pointed iron core is an iron core containing copper or a copper compound.
Further, the drug layer 21 is a mixture including a carrier and a pro-angiogenic factor.
Further, the carrier is polylactic acid.
Further, the easily degradable body material of the clamping part is polylactic acid.
Further, the pro-angiogenic factor is a prostaglandin.
According to the invention, through controllable degradation, the risk caused by retention of the vascular anastomat is reduced, the strength of the puncture part can be ensured through the pointed iron core, and the action effect is ensured; and can promote the growth and differentiation of vascular cells through drug loading, accelerate the anastomosis of blood vessels at the anastomotic site, reduce the generation of scars and reduce the tissue damage to the maximum extent.
Example 2
The drug-loaded degradable vascular anastomat is characterized by comprising main components 10 which are symmetrically arranged, wherein each main component comprises a clamping part 1, a puncture part 2 and a matching hole 3, and the puncture parts and the matching holes are symmetrically arranged on the clamping parts respectively;
and the puncturing parts of the adjacent main parts are matched and connected with the matching holes.
Further, the puncturing part is a pointed iron core, and a medicine layer 21 is coated outside the puncturing part.
Further, the clamping portion is annular.
Further, the clamping portion comprises a body 11 of a readily degradable material, the outer layer of which is coated with an iron-based coating 12.
Further, the matching hole is a hole which is in close fit with the pointed iron core.
Further, the pointed iron core is an iron core containing copper or a copper compound.
Further, the main part comprises at least 3 piercing parts.
Further, the drug layer 21 is a mixture including a carrier and a pro-angiogenic factor.
Further, the carrier is polylactic acid.
Further, the easily degradable body material of the clamping part is polylactic acid.
Further, the angiogenesis promoting factor is a complex of metallic copper.
Example 3
The drug-loaded degradable vascular anastomat is characterized by comprising main components 10 which are symmetrically arranged, wherein each main component comprises a clamping part 1, a puncture part 2 and a matching hole 3, and the puncture parts and the matching holes are symmetrically arranged on the clamping parts respectively;
and the puncturing parts of the adjacent main parts are matched and connected with the matching holes.
Further, the puncturing part is a pointed iron core, and a medicine layer 21 is coated outside the puncturing part.
Further, the clamping portion is annular.
Further, the clamping portion comprises a body 11 of a readily degradable material, the outer layer of which is coated with an iron-based coating 12.
Further, the matching hole is a hole which is in close fit with the pointed iron core.
Further, a chamfered structure 22 is arranged on the outer side of the pointed iron core.
Further, the pointed iron core is an iron core containing copper or a copper compound.
Further, the drug layer 21 is a pro-angiogenic factor.
Further, the easily degradable body material of the clamping part is polylactic acid.
Further, the pro-angiogenic factor is a prostaglandin.
According to the invention, through controllable degradation, the risk caused by retention of the vascular anastomat is reduced, the strength of the puncture part can be ensured through the pointed iron core, and the action effect is ensured; and can promote the growth and differentiation of vascular cells through drug loading, accelerate the anastomosis of blood vessels at the anastomotic site, reduce the generation of scars and reduce the tissue damage to the maximum extent.
Example 4
The drug-loaded degradable vascular anastomat is characterized by comprising main components 10 which are symmetrically arranged, wherein each main component comprises a clamping part 1, a puncture part 2 and a matching hole 3, and the puncture parts and the matching holes are symmetrically arranged on the clamping parts respectively;
and the puncturing parts of the adjacent main parts are matched and connected with the matching holes.
Further, the puncturing part is a pointed iron core, and a medicine layer 21 is coated outside the puncturing part.
Further, the clamping portion is annular.
Further, the clamping portion comprises a body 11 of a readily degradable material, the outer layer of which is coated with an iron-based coating 12.
Further, the matching hole is a hole which is in close fit with the pointed iron core.
Further, the pointed iron core is an iron core containing copper or a copper compound.
Further, the main part comprises at least 3 piercing parts.
Further, the drug layer 21 is a pro-angiogenic factor.
Further, the easily degradable body material of the clamping part is polylactic acid.
Furthermore, the angiogenesis promoting factor is one or more of prostaglandin, butyrylglycerol, hyaluronic acid metabolite, metal copper compound, vascular endothelial growth factor, and peptide angiogenesis factors such as aFGF, bFGF, angiogenin, PD-ECGF, TGF, TNF, etc.
Example 5
The present embodiment provides a drug-loaded degradable vascular anastomosis device having a structure consistent with that of embodiment 1, except that the carrier is hydroxyapatite.
Furthermore, the easily degradable body material of the clamping part is hydroxyapatite.
Furthermore, the angiogenesis promoting factor is a compound of aFGF and bFGF.
Example 6
The present embodiment provides a drug-loaded degradable vascular anastomosis device having a structure consistent with that of embodiment 1, except that, further, the carrier is collagen.
Further, the easily degradable body material of the clamping part is collagen.
Further, the angiogenesis promoting factor is a complex of a hyaluronic acid metabolite and angiogenin.
Example 7
The embodiment provides a medicine-carrying degradable vascular anastomat with the structure consistent with that of embodiment 2, and the difference is that further, the easily degradable body material of the clamping part is hydroxyapatite.
Furthermore, the angiogenesis promoting factor is a compound of aFGF and bFGF.
Example 8
The embodiment provides a structure and the same medicine-carrying degradable vascular anastomat of embodiment 2, and the difference is that further, the easily degradable body material of clamping part is collagen.
Further, the angiogenesis promoting factor is a complex of a hyaluronic acid metabolite and angiogenin.
Example 9
The embodiment provides a drug-loaded degradable vascular anastomat with the structure consistent with that of embodiment 1, except that the carrier is a composite of polylactic acid and hydroxyapatite.
Furthermore, the easily degradable body material of the clamping part is a composite of polylactic acid and hydroxyapatite.
Further, the angiogenesis promoting factor is the compound of butyryl glycerol and PD-ECGF.
Example 10
The present embodiment provides a drug-loaded degradable vascular anastomosis device having a structure consistent with that of embodiment 1, except that, further, the carrier is a composite of polylactic acid and collagen.
Furthermore, the easily degradable body material of the clamping part is the composition of polylactic acid and collagen.
Furthermore, the angiogenesis promoting factor is a metal copper compound and a vascular endothelial growth factor compound.
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein. Any reference sign in a claim should not be construed as limiting the claim concerned.
Furthermore, it should be understood that although the present description refers to embodiments, not every embodiment may contain only a single embodiment, and such description is for clarity only, and those skilled in the art should integrate the description, and the embodiments may be combined as appropriate to form other embodiments understood by those skilled in the art. It should be noted that the technical features not described in detail in the present invention can be implemented by any prior art.
Claims (10)
1. The drug-loaded degradable vascular anastomat is characterized by comprising main components which are symmetrically arranged, wherein each main component comprises a clamping part, a puncturing part and a matching hole, and the puncturing parts and the matching holes are symmetrically arranged on the clamping parts respectively;
the puncturing parts of the adjacent main parts are matched and connected with the matching holes;
the puncture part is a pointed iron core, and a medicine layer is coated outside the puncture part.
2. The drug-loaded degradable vascular anastomat of claim 1, wherein the clamping portion is annular.
3. The drug-loaded degradable vascular anastomat of claim 2, wherein the clamping portion comprises a body of easily degradable material, and an outer layer of the body is coated with an iron-based coating.
4. The drug-loaded degradable vascular anastomat of claim 1, wherein a chamfered structure is arranged on the outer side of the pointed iron core.
5. The drug-loaded degradable vascular anastomosis device according to claim 1, wherein the pointed iron core is an iron core of a copper-or copper-containing compound.
6. The drug-loaded degradable vascular anastomosis device according to claim 1, wherein the drug layer is a mixture comprising a carrier and a pro-vascular growth factor or a pro-vascular growth factor.
7. The drug-loaded degradable vascular anastomat of claim 5, wherein the carrier is one or a combination of polylactic acid, hydroxyapatite and collagen.
8. The drug-loaded degradable vascular anastomat of claim 3, wherein the easily degradable body material of the clamping part is one or a combination of polylactic acid, hydroxyapatite and collagen.
9. The drug-loaded degradable vascular anastomat of claim 6, wherein the angiogenesis promoting factor is a prostaglandin, butyrylglycerol, a hyaluronic acid metabolite, a complex of metallic copper, a vascular endothelial growth factor and a complex of one or more of aFGF, bFGF, angiogenin, PD-ECGF, TGF and TNF.
10. The drug-loaded degradable vascular anastomosis device according to claim 1, wherein the main part comprises at least 3 puncture parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010901258.4A CN112155625A (en) | 2020-08-31 | 2020-08-31 | Medicine-carrying degradable blood vessel anastomat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010901258.4A CN112155625A (en) | 2020-08-31 | 2020-08-31 | Medicine-carrying degradable blood vessel anastomat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112155625A true CN112155625A (en) | 2021-01-01 |
Family
ID=73858635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010901258.4A Pending CN112155625A (en) | 2020-08-31 | 2020-08-31 | Medicine-carrying degradable blood vessel anastomat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112155625A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113558696A (en) * | 2021-07-08 | 2021-10-29 | 河南省人民医院 | Blood vessel anastomat for kidney transplantation operation |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1566091A (en) * | 2003-07-04 | 2005-01-19 | 中国人民解放军军事医学科学院毒物药物研究所 | Molindone derivatives and use for preparing antineoplastic medicine thereof |
| US20100076556A1 (en) * | 2008-09-24 | 2010-03-25 | Intergran technologies, Inc. | In-vivo biodegradable medical implant |
| CN105797220A (en) * | 2014-12-31 | 2016-07-27 | 先健科技(深圳)有限公司 | Degradable ferrous alloy stent |
| CN207886229U (en) * | 2017-06-23 | 2018-09-21 | 韩培 | Degradable blood vessel anastomosis device |
| CN213156148U (en) * | 2020-08-31 | 2021-05-11 | 广东工业大学 | Medicine-carrying degradable blood vessel anastomat |
-
2020
- 2020-08-31 CN CN202010901258.4A patent/CN112155625A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1566091A (en) * | 2003-07-04 | 2005-01-19 | 中国人民解放军军事医学科学院毒物药物研究所 | Molindone derivatives and use for preparing antineoplastic medicine thereof |
| US20100076556A1 (en) * | 2008-09-24 | 2010-03-25 | Intergran technologies, Inc. | In-vivo biodegradable medical implant |
| CN105797220A (en) * | 2014-12-31 | 2016-07-27 | 先健科技(深圳)有限公司 | Degradable ferrous alloy stent |
| CN207886229U (en) * | 2017-06-23 | 2018-09-21 | 韩培 | Degradable blood vessel anastomosis device |
| CN213156148U (en) * | 2020-08-31 | 2021-05-11 | 广东工业大学 | Medicine-carrying degradable blood vessel anastomat |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113558696A (en) * | 2021-07-08 | 2021-10-29 | 河南省人民医院 | Blood vessel anastomat for kidney transplantation operation |
| CN113558696B (en) * | 2021-07-08 | 2023-05-16 | 河南省人民医院 | Vascular anastomat for kidney transplantation operation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tellis et al. | Expanded polytetrafluoroethylene graft fistula for chronic hemodialysis. | |
| Yun et al. | Randomized trial of endoscopic versus open vein harvest for coronary artery bypass grafting: six-month patency rates | |
| US20140222067A1 (en) | Minimally invasive surgery, including vascular closure, and associated sealants | |
| Liu et al. | Adhesive anastomosis for organ transplantation | |
| Liu et al. | Nonsuture anastomosis of arteries and veins using the magnetic pinned-ring device: a histologic and scanning electron microscopic study | |
| CN213156148U (en) | Medicine-carrying degradable blood vessel anastomat | |
| CN112155625A (en) | Medicine-carrying degradable blood vessel anastomat | |
| Heitzer et al. | Microvascular anastomosis techniques using the medical adhesive VIVO and expandable micro-stents in a rat carotid artery model | |
| Pettersen et al. | Pedicled vein grafts in coronary surgery: perioperative data from a randomized trial | |
| Shah et al. | Complete percutaneous decannulation from femoral venoarterial extracorporeal membrane oxygenation | |
| Jiang et al. | Stable hemodynamics within “no-touch” saphenous vein graft | |
| Johnson et al. | The relationship of the method of suture to the growth of end-to-end arterial anastomoses | |
| Wijeyaratne et al. | Safety and efficacy of electrospun polycarbonate-urethane vascular graft for early hemodialysis access: first clinical results in man | |
| Cho et al. | Fibrin glue application in microvascular anastomosis: comparative study of two free flaps series | |
| Fujimaki et al. | Experimental micro-anastomosis of 0· 4–0· 5 mm vessels | |
| Ji et al. | In Situ Skeletonized Right Internal Mammary Artery Bypass Grafting to Left Anterior Descending Artery Feasibility, Mid-Term Efficacy, and Risk Factors for Graft Failure | |
| WO1999018931A1 (en) | Use of fibrin sealant to maintain hemostasis, lymphostasis and prevent local accumulation of body fluids | |
| Zhang et al. | A modified technique of renal artery anastomosis in rat kidney transplantation | |
| US20210244409A1 (en) | Suture material developed for end-to-end anastomosis | |
| Leppäniemi et al. | Common bile duct repair with titanium staples: comparison with suture closure | |
| RU2801037C1 (en) | Method of stimulating the regeneration of intestinal anastomoses using autogenous growth factors | |
| RU2786831C1 (en) | Method for providing distal radial and radial access from one hand for interventions on chronic coronary occlusions | |
| RU2771763C1 (en) | Method for hemostasis in bleeding from an unresectable rectal tumor | |
| RU2771073C1 (en) | Method for hemostasis in bleeding from a tumour in the hepato-pancreato-biliary region, accompanied by haemobilia | |
| RU2733506C1 (en) | Method of temporary haemostasis accompanying dissection of the bulbose urethra ventral surface in the course of anastomotic urethroplasty without intersecting the spongy body |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |